Trial Profile
A Phase II, Randomized, Parallel-Group, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and Compared With Vedolizumab in Patients With Moderate to Severe Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Efmarodocokin alfa (Primary) ; Vedolizumab
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Genentech
- 17 Dec 2021 Status changed from active, no longer recruiting to completed.
- 17 Jun 2021 Status changed from recruiting to active, no longer recruiting.
- 05 Mar 2021 Planned End Date changed from 12 Jan 2022 to 28 Jul 2022.